Blueprint Medicines Corp

Blueprint Medicines — PIONEER Part 2 Top-line Results call (August 2022)

19 slides from Blueprint Medicines's conference presentation, Aug 17, 2022

  1. Slide 1: PIONEER Part 2 Top-line Results: AYVAKIT in Non-Advanced Systemic Mastocytosis

    Slide 1: PIONEER Part 2 Top-line Results: AYVAKIT in Non-Advanced Systemic Mastocytosis

    © 2022 Blueprint Medicines Corporation R.S., living with systemic mastocytosis PIONEER Part 2 Top-line Results AYVAKIT® (avapritinib) in Non-Advanced Systemic Mastocytosis August 17, 2022

  2. Slide 2: Blueprint Medicines call participants

    Slide 2: Blueprint Medicines call participants

    Blueprint Medicines call participants 2 Introduction Kate Haviland, Chief Executive Officer Positive PIONEER Part 2 Topline Results Becker Hewes, MD, Chief Medical Officer Investigator Commentary Mariana Castells, MD, PhD, Director, Mastocytosis Center, Brigham and Women’s Hospital Q&A All PREPARED

  3. Slide 3: Forward-looking statements

    Slide 3: Forward-looking statements

    Forward-looking statements 3 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans to submit a supplemental new drug application (sNDA) to the U.S. Food a

  4. Slide 4: AYVAKIT has the potential to be the first disease-modifying therapy for non-advanced SM

    Slide 4: AYVAKIT has the potential to be the first disease-modifying therapy for non-advanced SM

    AYVAKIT® (avapritinib) has the potential to be the first disease-modifying therapy for non-advanced SM SM, systemic mastocytosis 4 POSITIVE TOPLINE RESULTS FULL RESULTS EXPECTED AT UPCOMING MEDICAL CONFERENCE Not for promotional use.

  5. Slide 5: Today's news reflects a decade of commitment and collaboration

    Slide 5: Today's news reflects a decade of commitment and collaboration

    Today’s news reflects a decade of commitment and collaboration SM, systemic mastocytosis; FDA, U.S. Food & Drug Administration; US, United States; EU, Europe 5 • Generated robust datasets on SM disease burden in collaboration with patients, healthcare providers, and patient advocacy groups • >100 sc

  6. Slide 6: AYVAKIT demonstrated highly significant impact on primary and all key secondary endpoints

    Slide 6: AYVAKIT demonstrated highly significant impact on primary and all key secondary endpoints

    AYVAKIT demonstrated highly significant and clinically meaningful impact on the primary and all key secondary endpoints Data cutoff as of June 23, 2022. 1. One-sided p-value < 0.025 indicates statistical significance. 2. For secondary endpoints, reductions in TSS and objective measures of mast cell

  7. Slide 7: Positive PIONEER Part 2 Topline Results

    Slide 7: Positive PIONEER Part 2 Topline Results

    Positive PIONEER Part 2 Topline Results Becker Hewes, MD, Chief Medical Officer

  8. Slide 8: Largest clinical trial in non-advanced SM conducted to-date

    Slide 8: Largest clinical trial in non-advanced SM conducted to-date

    Largest clinical trial in non-advanced SM conducted to-date Data cutoff as of June 23, 2022. QD, once daily; BAC, best available care; TSS, total symptom score; SD, standard deviation 8 Not for promotional use. Primary endpoint AYVAKIT 25 mg QD + BAC Placebo QD + BAC (Control) Mean change in TSS at

  9. Slide 9: AYVAKIT demonstrated highly significant impact on primary and all key secondary endpoints

    Slide 9: AYVAKIT demonstrated highly significant impact on primary and all key secondary endpoints

    AYVAKIT demonstrated highly significant and clinically meaningful impact on the primary and all key secondary endpoints Data cutoff as of June 23, 2022. 1. One-sided p-value < 0.025 indicates statistical significance. 2. For secondary endpoints, reductions in TSS and objective measures of mast cell

  10. Slide 10: Decreases in patient-reported symptoms and objective measures of disease burden

    Slide 10: Decreases in patient-reported symptoms and objective measures of disease burden

    Decreases in patient-reported symptoms and objective measures of disease burden 1. After 24 weeks, all patients had the option to cross over into Part 3 and receive treatment with AYVAKIT 25 mg QD. TSS, total symptom score; CI, confidence interval. 10 Mean Change in TSS [95 % CI] AYVAKIT Control PAR

  11. Slide 11: AYVAKIT was well-tolerated with a safety profile favorable to control

    Slide 11: AYVAKIT was well-tolerated with a safety profile favorable to control

    AYVAKIT was well-tolerated with a safety profile favorable to control Data cutoff as of June 23, 2022. 1. Cognitive effect AEs refer to 17 pooled terms identified across AYVAKIT clinical studies. AE, adverse event; SAE, serious adverse event; TRAE, treatment-related adverse event; ICB, intracranial

  12. Slide 12: Investigator Commentary

    Slide 12: Investigator Commentary

    Investigator Commentary Mariana Castells, MD, PhD, Director, Mastocytosis Center Brigham and Women’s Hospital

  13. Slide 13: Dr. Mariana Castells, MD, PhD

    Slide 13: Dr. Mariana Castells, MD, PhD

    Dr. Mariana Castells, MD, PhD • Brigham and Women’s Hospital o Sees approximately 2,000 SM patients per year o Director, Mastocytosis Center; Drug Hypersensitivity and Desensitization Center; Allergy and Clinical Immunology Training Program • Professor, Harvard Medical School • Board of Directors: A

  14. Slide 14: Upon activation of mast cells, proinflammatory mediators are released

    Slide 14: Upon activation of mast cells, proinflammatory mediators are released

    Upon activation of mast cells, proinflammatory mediators are released 1. Castells M, Austen KF. Int Arch Allergy Immunol. 2002 Feb;127(2):147-52. 2. Castells M. J Allergy and Clin Immunol. 2017 Aug;140(2):321-333. Not for promotional use. 14

  15. Slide 15: Uncontrolled mast cell activation in SM causes severe and unpredictable symptoms

    Slide 15: Uncontrolled mast cell activation in SM causes severe and unpredictable symptoms

    Uncontrolled mast cell activation in SM causes severe and unpredictable symptoms across multiple organ systems1-3 1. Theoharides TC et al. N Engl J Med. 2015;373(2):163-172. 2. Gilreath JA et al. Clin Pharmacol. 2019;11:77-92. 3. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505- 525.

  16. Slide 16: Case study #1 in a patient with significant skin and GI involvement

    Slide 16: Case study #1 in a patient with significant skin and GI involvement

    Case study #1 in a patient with significant skin and GI involvement 16 Spots Score 9 After almost two years on AYVAKIT, patient reports “life changing” improvement, including continued improvement in QoL, no new symptoms, and reduction in polypharmacy. This patient remains on AYVAKIT today. Severe o

  17. Slide 17: Case study #2 in a patient heavily pretreated with cytoreductive therapies

    Slide 17: Case study #2 in a patient heavily pretreated with cytoreductive therapies

    Case study #2 in a patient heavily pretreated with cytoreductive therapies and ongoing polypharmacy 17 Spots Score 9 Patient reports drastic symptom improvement including reduction in baseline skin lesions, rare GI symptoms, and consistent improvement in bone pain. This patient remains on AYVAKIT to

  18. Slide 18: PIONEER Part 2 positive topline results

    Slide 18: PIONEER Part 2 positive topline results

    PIONEER Part 2 positive topline results 18 Not for promotional use. AYVAKIT demonstrated highly significant and clinically meaningful impact on the primary and all key secondary endpoints 1 AYVAKIT was well-tolerated with a safety profile favorable to control 2 Detailed results expected to be presen

  19. Slide 19: Thank you

    Slide 19: Thank you

    Thank you Blueprint Medicines, AYVAKIT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.

Source: SEC EDGAR · 8-K filed Aug 17, 2022

More decks from Blueprint Medicines Corp